Trials / Completed
CompletedNCT03356834
Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF
Change of Renal Function and Bone Mineral Density Marker in Chronic Hepatitis B Patients Switching From TDF to TAF vs. Maintaining TDF
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 575 (actual)
- Sponsor
- Humanity and Health Research Centre · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In Chronic hepatitis B (CHB) patients receiving long-term sequential Neucleos(t)ides(NAs), majority of these CHB patients experienced drug resistance and switched to Tenofovir disoproxil fumaratate(TDF). However, some of patients on long term TDF experienced impairment of renal function and bone mineral density. After Tenofovir alafenamide(TAF) was in clinical practice, these group of patients got an clinical option to switch from TDF to TAF. The investigators designed a prospective cohort study to evaluate the real life effectiveness and safety in participants with chronic HBV infection switch from TDF to TAF vs. maintaining on TDF.
Detailed description
Tenofovir disoproxil fumarate(TDF) have been associated with renal toxicity and reduced bone mineral density. Tenofovir alafenamide(TAF) is a novel tenofovir prodrug that reduces tenofovir plasma concentrations by 90%, thereby decreasing off-target side-effects. The investigators aimed to assess whether efficacy, safety, and tolerability were non-inferior in participants switched to TAF versus in those remaining on TDF. This is a prospective clinical study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir alafenamide(TAF) | 25 mg tablet administered orally once daily |
| DRUG | Tenofovir disoproxil fumarate(TDF) | 300 mg tablet administered orally once daily |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
- First posted
- 2017-11-29
- Last updated
- 2025-03-26
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT03356834. Inclusion in this directory is not an endorsement.